Silexion Therapeutics (SLXN) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silexion Therapeutics is the larger company by market cap ($3.4 million vs $3.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLXN | XRTX |
|---|---|---|
| Share price | $0.2349 | $1.85 |
| Market cap | $3.40M | $3.36M |
| 1-day change | -7.37% | +6.02% |
| Forward P/E | — | 2.31 |
| EPS (TTM) | $-27.21 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.70 | $7.05 |
| 52-week low | $0.222 | $1.59 |
| Distance from 52-week high | -99.42% | -73.76% |
| Analyst consensus | none | — |
| Avg. price target upside | +2028.57% | — |
| Average volume | 9.90M | 376.30K |
| Shares outstanding | 14.47M | 1.82M |
| Employees | 13 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Healthcare · Biotechnology · 13 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Healthcare · Biotechnology
SLXN vs XRTX FAQ
Which is bigger, Silexion Therapeutics or XORTX Therapeutics?
Silexion Therapeutics (SLXN) is larger, with a market capitalization of $3.40M compared with $3.36M for XORTX Therapeutics (XRTX).
Are Silexion Therapeutics and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.